Screener
Xeris Biopharma Holdings, Inc. XERS Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s long-term debt?
- Xeris Biopharma Holdings, Inc. (XERS) reported long-term debt of $188.81M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s long-term debt changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s long-term debt decreased by 13.6% year-over-year, from $218.63M to $188.81M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s long-term debt has grown at a 20.4% compound annual growth rate (CAGR), from $87.02M to $220.34M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Xeris Biopharma Holdings, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude